Rafferty Asset Management
XERS icon

Rafferty Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Rafferty Asset Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Sell
22,889
-1,358
-6% -$8.67K ﹤0.01% 1115
2026
Q1 		$141K Sell
24,247
-9,442
-28% -$62.6K ﹤0.01% 1041
2025
Q4 		$264K Buy
33,689
+16,278
+93% +$128K ﹤0.01% 1022
2025
Q3 		$142K Sell
17,411
-8,492
-33% -$56.4K ﹤0.01% 1090
2025
Q2 		$121K Buy
25,903
+10,900
+73% +$49.9K ﹤0.01% 1066
2025
Q1 		$82.4K Sell
15,003
-2,717
-15% -$11K ﹤0.01% 1049
2024
Q4 		$60.1K Sell
17,720
-1,392
-7% -$4.48K ﹤0.01% 1137
2024
Q3 		$54.5K Sell
19,112
-424
-2% -$1.09K ﹤0.01% 1136
2024
Q2 		$44K Sell
19,536
-1,677
-8% -$3.38K ﹤0.01% 1168
2024
Q1 		$46.9K Buy
+21,213
New +$54.9K ﹤0.01% 1078
2022
Q3 		– Sell
-35,248
Closed -$54K – 1260
2022
Q2 		$54K Buy
35,248
+4,105
+13% +$8.66K ﹤0.01% 1098
2022
Q1 		$80K Sell
31,143
-12,198
-28% -$29.8K ﹤0.01% 1189
2021
Q4 		$127K Buy
43,341
+14,174
+49% +$30.6K ﹤0.01% 1246
2021
Q3 		$71K Buy
+29,167
New +$84.7K ﹤0.01% 1248

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Rafferty Asset Management's XERS Position: Q2 2026 in Review

Rafferty Asset Management reduced its Xeris Biopharma Holdings (XERS) stake by 5.6% in Q2 2026, selling an estimated $8.67K and leaving 22,889 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

Rafferty Asset Management first reported a position in XERS in Q3 2021 and has held it in 14 quarters since. The position peaked at $264K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Rafferty Asset Management held 22,889 shares of Xeris Biopharma Holdings worth $181K as of Q2 2026.
  • Rafferty Asset Management sold 1,358 Xeris Biopharma Holdings shares in Q2 2026, an estimated $8.67K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #1115 holding.
  • Rafferty Asset Management first reported a position in Xeris Biopharma Holdings in Q3 2021 and has held it in 14 quarters since.
  • Rafferty Asset Management's Xeris Biopharma Holdings position peaked at $264K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.